Skip to main content
. Author manuscript; available in PMC: 2023 Dec 4.
Published in final edited form as: Arthritis Care Res (Hoboken). 2022 Jan 17;74(3):484–492. doi: 10.1002/acr.24485

Table 5:

Multivariate Analysis of Factors Associated with Quality Measures from Medical Record Abstraction at One Year

Dependent Variable Evaluated in Model Model Type n Independent Variable Estimate p-value

Beta 95% CI)
Number of rheumatologist visits in past year Poisson regression 122 patients Age, linear −0.002 (−0.012, 0.009) 0.73
Male sex 0.01 (−0.357, 0.379) 0.95
Telemedicine group −0.02 (−0.293,0.249) 0.87
Number of visits in year prior to study 0.11 (0.016, 0.201) 0.02
Odds ratio (95% CI)
Documentation of disease activity at the visit Multivariate logistic regression 217 visits Age, linear 0.99 (0.97,1.02) 0.66
Male sex 0.52 (0.21,1.30) 0.16
Telemedicine group 0.54 (0.29,1.02) 0.06
RAPID3 at baseline 0.89 (0.83,0.95) 0.0004*
Number of visits in year prior to study 0.76 (0.60,0.97) 0.02
Change in medications is prescribed when disease activity is moderate or high Multivariate logistic regression 46 visits Age (linear) 1.03 (0.96,1.11) 0.38
Male sex 1.92 (0.09,42.5) 0.68
Telemedicine group 2.44 (0.45,13.2) 0.3
Number of visits in year prior to study 0.42 (0.18,0.98) 0.04
Functional status assessment documentation Multivariate logistic regression 217 visits Age, linear 1.00 (0.97,1.03) 0.85
Male sex 1.40 (0.60,3.2) 0.44
Telemedicine group 1.48 (0.75,2.90) 0.26
High rheumatologist telemedicine rate 0.04 (0.01,0.20) <0.001*
Number of visits in year prior to study 1.30 (1.04,1.62) 0.02*
DMARD prescribed in past year Multivariate logistic regression 122 Age, linear 1.27 (1.03,1.55) 0.02
Male sex 0.06 (0.002,1.72) 0.1
Telemedicine group 1.04 (0.05,21.3) 0.98

CI: Confidence Interval; DMARD: disease-modifying anti-rheumatic drug